Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22982793 | 0.84 | SMN1; SMN2 (0.57) | MAPTSMN1; SMN2ALDH1A1GAA | |
| SCHEMBL23008892 | 0.79 | SMN1; SMN2 (0.75) | MAPTSMN1; SMN2AKR1C3ALDH1A1GAA | |
| SCHEMBL22982272 | 0.79 | MAPT (0.56) | MAPTSMN1; SMN2AKR1C3ALDH1A1GAA | |
| SCHEMBL8637476 | 0.78 | SMN1; SMN2 (0.56) | MAPTSMN1; SMN2ALDH1A1GAA | |
| SCHEMBL7334978 | 0.78 | CHKA (0.61) | MAPTDRD2SMN1; SMN2AKR1C3ALDH1A1 | |
| SCHEMBL2989541 | 0.77 | CYP2D6 (0.67) | SMN1; SMN2ALDH1A1GAATSHR | |
| SCHEMBL22982591 | 0.77 | NPC1 (0.57) | MAPTDRD2SMN1; SMN2GAA | |
| SCHEMBL2999120 | 0.77 | HTT (0.69) | MAPTSMN1; SMN2ALDH1A1GAATSHR | |
| SCHEMBL10402759 | 0.75 | CHKA (0.50) | MAPTSMN1; SMN2AKR1C3ALDH1A1GAA | |
| SCHEMBL10402761 | 0.75 | CHKA (0.50) | MAPTSMN1; SMN2AKR1C3TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12435067-B2 | Truncated itraconazole analogues and methods of use thereof | UNIVERSITY OF CONNECTICUT (US) | 2025-10-07 | — | — | US | disclosed |
| US-20220324849-A1 | TRUNCATED ITRACONAZOLE ANALOGUES AND METHODS OF USE THEREOF | UNIVERSITY OF CONNECTICUT | 2022-10-13 | — | — | US | disclosed |
| WO-2021030174-A1 | TRUNCATED ITRACONAZOLE ANALOGUES AND METHODS OF USE THEREOF | UNIVERSITY OF CONNECTICUT (US) | 2021-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12435067-B2 | Truncated itraconazole analogues and methods of use thereof | GLI1, SHH, SMO | MAPT 4255/4885DRD2 4833/4885SMN1; SMN2 3996/4885 |
| US-20220324849-A1 | TRUNCATED ITRACONAZOLE ANALOGUES AND METHODS OF USE THEREOF | GLI1, SHH, SMO | MAPT 4255/4885DRD2 4833/4885SMN1; SMN2 3996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.